RAG-17 shows promise in SOD1-ALS trial, reducing damage markers
WHY IT MATTERS
If you have SOD1-ALS, this is one of the first treatments specifically designed for your genetic form of the disease, and early signs suggest it may slow the damage happening in your body.
Scientists are testing a new drug called RAG-17 for people with a specific type of ALS (a disease that weakens muscles over time) caused by a SOD1 gene mutation. Early results show the drug was safe at different doses and made important disease markers improve. This is early-stage testing, but it's a promising first step.
RAG-17, an experimental treatment Ractigen Therapeutics is developing for people with amyotrophic lateral sclerosis (ALS) who carry a SOD1 mutation (SOD1-ALS), was well tolerated at multiple doses and led to profound changes in disease biomarkers, preliminary trial data showed. The data cover the first part of an ongoing Phase 1/2 clinical trial (NCT06556394), in which […] The post RAG-17 shows promise in SOD1-ALS trial, reducing damage markers appeared first on ALS News Today .
ASK YOUR DOCTOR
Ask your neurologist if you have SOD1-ALS and whether you might be eligible for the RAG-17 trial (NCT06556394) — enrollment details should be available through your doctor or ClinicalTrials.gov.